Noriyuki Miyaue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Noriyuki Miyaue has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Masahiro Nagai
Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Toon, Ehime, Japan
26 shared publicationsHayato Yabe
Department of Neurology, Saiseikai Matsuyama Hospital, Matsuyama, Ehime, Japan
25 shared publicationsRina Ando
Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Toon, Japan
13 shared publicationsYuki Yamanishi
Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Toon, Ehime, Japan
13 shared publicationsSatoshi Tada
Department of Clinical Pharmacology and therapeutics, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
11 shared publications- Masahiro Nagai
Department of Neurology and Clinical Pharmacology, Ehime University Hospital, Japan; Clinical Therapeutic Trial Center, Ehime University Hospital, Japan
7 shared publications
Latest Publications
- 24 August 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 151, 108949
Helicobacter pylori eradication status is associated with lower motor severity despite similar levodopa pharmacokinetics in Parkinson's disease
- 24 August 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 151, 108949
Helicobacter pylori eradication status is associated with lower motor severity despite similar levodopa pharmacokinetics in Parkinson's disease
- 22 April 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 147, 108322
Disease duration–dependent alteration of regulatory natural killer cells in patients with Parkinson's disease
- 22 April 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 147, 108322
Disease duration–dependent alteration of regulatory natural killer cells in patients with Parkinson's disease
- Open Access
- 28 February 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 46 (1)
A Dopamine D1-Like Receptor Agonist Ameliorates Traumatic Brain Injury Through its Immunosuppressive Effects
Traumatic brain injury (TBI) causes progressive nervous tissue degeneration long after the initial injury due to secondary neuroinflammatory reactions. G p
- 28 February 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 46 (1)
Open AccessA Dopamine D1-Like Receptor Agonist Ameliorates Traumatic Brain Injury Through its Immunosuppressive Effects
Traumatic brain injury (TBI) causes progressive nervous tissue degeneration long after the initial injury due to secondary neuroinflammatory reactions. G p
- Open Access
- 1 January 2026
- Published by Societas Neurologica Japonica in Rinsho Shinkeigaku
- Vol. 66 (7) , cn-002241-472
Word fluency for “Ka” in Parkinson’s disease patients: comparison with memory clinic patients
パーキンソン病(Parkinson’s disease,以下PDと略記)患者の語想起課題に関する国内研究は限られる.本研究では,Japanese version of the Montreal Cognitive Assessment(MoCA-J)の語想起課題(「か」で始まる語)における語数および語の質的特性を,PD患者100名ともの忘れ外来受診患者100名で比較した.Mini-Mental State Examination(MMSE)はPD群27.6点,もの忘れ群24.4点,MoCA-JはPD群23.5点,もの忘れ群18.7点でいずれもPD群が高値だった.語想起数はPD群9.1個,もの忘れ群9.2個で,認知機能スコアと語数には正の相関を認めた.語種はPD群318種,もの忘れ群285種でPD群では形容詞が少なかった.意味カテゴリ分類(物の名前,動作関連,感情・状態等)では群間差を認めなかった.
- 1 January 2026
- Published by Societas Neurologica Japonica in Rinsho Shinkeigaku
- Vol. 66 (7) , cn-002241-472
Open AccessWord fluency for “Ka” in Parkinson’s disease patients: comparison with memory clinic patients
パーキンソン病(Parkinson’s disease,以下PDと略記)患者の語想起課題に関する国内研究は限られる.本研究では,Japanese version of the Montreal Cognitive Assessment(MoCA-J)の語想起課題(「か」で始まる語)における語数および語の質的特性を,PD患者100名ともの忘れ外来受診患者100名で比較した.Mini-Mental State Examination(MMSE)はPD群27.6点,もの忘れ群24.4点,MoCA-JはPD群23.5点,もの忘れ群18.7点でいずれもPD群が高値だった.語想起数はPD群9.1個,もの忘れ群9.2個で,認知機能スコアと語数には正の相関を認めた.語種はPD群318種,もの忘れ群285種でPD群では形容詞が少なかった.意味カテゴリ分類(物の名前,動作関連,感情・状態等)では群間差を認めなかった.
- Open Access
- 1 January 2026
- Published by Wiley in Parkinson's Disease
- Vol. 2026 (1)
Serum GDF‐15 Levels Correlate With Motor and Nonmotor Symptom Domains and Overall Disease Severity in Patients With Parkinson’s Disease
Objective: Growth differentiation factor 15 (GDF‐15) has emerged as a potential biomarker for neurodegenerative diseases. Although elevated serum GDF‐15 levels have been reported in Parkinson’s disease (PD), their association with clinical features has not been fully characterized. Methods: We evaluated serum GDF‐15 concentrations in 40 patients with PD and analyzed their relationships with clinical measures, including motor severity (MDS‐UPDRS), quality of life (PDQ‐39), sleep disturbances (PDSS‐2), autonomic symptoms (SCOPA‐AUT), and cognitive function (MoCA‐J). Results: Higher serum GDF‐15 levels were associated with older age and greater symptom burden across multiple domains. Significant relationships were observed with MDS‐UPDRS Parts I–III and total scores, PDQ‐39 summary index and bodily discomfort index, two different PDSS‐2 domains (motor symptoms at night and PD symptoms at night), and SCOPA‐AUT total and gastrointestinal dysfunction scores. After adjusting for age, the associations between serum GDF‐15 levels and MDS‐UPDRS Part II, Part III, and total scores remained significant. No sex‐related differences were detected. A trend toward lower MoCA‐J scores with increasing GDF‐15 levels was observed but did not reach statistical significance. Conclusion: Serum GDF‐15 levels are linked to both motor and nonmotor aspects of PD and may reflect overall disease burden. Further longitudinal studies are needed to determine their value for disease monitoring and prognosis.
- 1 January 2026
- Published by Wiley in Parkinson's Disease
- Vol. 2026 (1)
Open AccessSerum GDF‐15 Levels Correlate With Motor and Nonmotor Symptom Domains and Overall Disease Severity in Patients With Parkinson’s Disease
Objective: Growth differentiation factor 15 (GDF‐15) has emerged as a potential biomarker for neurodegenerative diseases. Although elevated serum GDF‐15 levels have been reported in Parkinson’s disease (PD), their association with clinical features has not been fully characterized. Methods: We evaluated serum GDF‐15 concentrations in 40 patients with PD and analyzed their relationships with clinical measures, including motor severity (MDS‐UPDRS), quality of life (PDQ‐39), sleep disturbances (PDSS‐2), autonomic symptoms (SCOPA‐AUT), and cognitive function (MoCA‐J). Results: Higher serum GDF‐15 levels were associated with older age and greater symptom burden across multiple domains. Significant relationships were observed with MDS‐UPDRS Parts I–III and total scores, PDQ‐39 summary index and bodily discomfort index, two different PDSS‐2 domains (motor symptoms at night and PD symptoms at night), and SCOPA‐AUT total and gastrointestinal dysfunction scores. After adjusting for age, the associations between serum GDF‐15 levels and MDS‐UPDRS Part II, Part III, and total scores remained significant. No sex‐related differences were detected. A trend toward lower MoCA‐J scores with increasing GDF‐15 levels was observed but did not reach statistical significance. Conclusion: Serum GDF‐15 levels are linked to both motor and nonmotor aspects of PD and may reflect overall disease burden. Further longitudinal studies are needed to determine their value for disease monitoring and prognosis.
- 19 August 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 139, 108006
Sex differences in the pharmacokinetics of levodopa and carbidopa in patients with Parkinson’s disease
- 19 August 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 139, 108006
Sex differences in the pharmacokinetics of levodopa and carbidopa in patients with Parkinson’s disease
- Open Access
- 18 March 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 11 (1) , 1-9
Association of Enterococcus faecalis and tyrosine decarboxylase gene levels with levodopa pharmacokinetics in Parkinson’s disease
Multiple factors affect the absorption of orally administered levodopa, the gold standard for the treatment of Parkinson’s disease (PD). Enterococcus faecalis (E. faecalis) expresses the enzyme tyrosine decarboxylase (tyrDC), which metabolizes levodopa into dopamine and thereby may influence its absorption in patients with PD. This study investigated the association between fecal E. faecalis and tyrDC gene levels and the pharmacokinetics of orally administered levodopa in 21 patients with PD. Our results revealed a significant association between elevated fecal levels of E. faecalis and tyrDC gene levels and reduced peak plasma levodopa concentrations. Additionally, among patients receiving levodopa-carbidopa intestinal gel treatment, strong positive correlations were observed between E. faecalis and tyrDC gene levels in fecal samples and those from the tip of the jejunal tube. Further prospective studies are required to explore the potential role of gut microbiota as a therapeutic target in patients with PD.
- 18 March 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 11 (1) , 1-9
Open AccessAssociation of Enterococcus faecalis and tyrosine decarboxylase gene levels with levodopa pharmacokinetics in Parkinson’s disease
Multiple factors affect the absorption of orally administered levodopa, the gold standard for the treatment of Parkinson’s disease (PD). Enterococcus faecalis (E. faecalis) expresses the enzyme tyrosine decarboxylase (tyrDC), which metabolizes levodopa into dopamine and thereby may influence its absorption in patients with PD. This study investigated the association between fecal E. faecalis and tyrDC gene levels and the pharmacokinetics of orally administered levodopa in 21 patients with PD. Our results revealed a significant association between elevated fecal levels of E. faecalis and tyrDC gene levels and reduced peak plasma levodopa concentrations. Additionally, among patients receiving levodopa-carbidopa intestinal gel treatment, strong positive correlations were observed between E. faecalis and tyrDC gene levels in fecal samples and those from the tip of the jejunal tube. Further prospective studies are required to explore the potential role of gut microbiota as a therapeutic target in patients with PD.
- 28 August 2024
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 465, 123202
Effect of concomitant use of esomeprazole on levodopa pharmacokinetics and clinical symptoms in patients with Parkinson's disease
- 28 August 2024
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 465, 123202
Effect of concomitant use of esomeprazole on levodopa pharmacokinetics and clinical symptoms in patients with Parkinson's disease